agonist

(redirected from Partial agonists)
Also found in: Dictionary, Thesaurus, Encyclopedia.

agonist

 [ag´o-nist]
in pharmacology, a drug that has affinity for the cellular receptors of another drug or natural substance and that produces a physiological effect.

ag·o·nist

(ag'on-ist),
1. Denoting a muscle in a state of contraction, with reference to its opposing muscle, or antagonist.
2. A drug capable of combining with receptors to initiate drug actions; it possesses affinity and intrinsic activity.
[G. agōn, a contest]

agonist

/ag·o·nist/ (ag´ah-nist)
1. one involved in a struggle or competition.
3. in pharmacology, a drug that has an affinity for and stimulates physiologic activity at cell receptors normally stimulated by naturally occurring substances.

agonist

(ăg′ə-nĭst)
n.
1. Physiology A contracting muscle that is resisted or counteracted by another muscle, the antagonist.
2. A substance that can combine with a receptor on a cell to initiate signal transduction.

agonist

[ag′ənist]
Etymology: Gk, agon, struggle
1 a contracting muscle whose contraction is opposed by another muscle (an antagonist).
2 a drug or other substance having a specific cellular affinity that produces a predictable response.

Agonist

Anatomy Agonist muscle, prime mover. A muscle that causes a particular movement to occur, creating a normal range of movement in a joint by contracting; a muscle which moves in one general direction.
Molecular biology A ligand which binds a receptor at a site adjacent to the active site.
Pharmacology Agonist medication. A chemical entity that does not naturally occur in the body and acts on one or more receptors (e.g., mu, delta, and kappa opiate receptors) by structural mimicry of the receptors’ natural ligand(s). It may be an agonist or partial agonist for a particular receptor, promoting a receptor-mediated biological response, often by competing with another substance (usually the natural or native substance) at the same receptor. A partial agonist produces less than the maximum effect even if given in a concentration sufficient to bind with all available receptors.

agonist

Pharmacology A substance that promotes a receptor-mediated biologic response, often by competing with another substance at the same receptor. Cf Antagonist.

ag·o·nist

(ag'ŏn-ist)
1. A muscle (or group of muscles) whose contraction produces a specific action with reference to its antagonist muscle (or muscles).
2. A drug capable of combining with receptors to initiate drug actions; it possesses affinity and intrinsic activity.
[G. agōn, a contest]

agonist

1. A molecule, such as a HORMONE, NEUROTRANSMITTER or drug, that attaches (binds) to a cell receptor site to produce an effect on the cell. Many drugs are agonists having an effect similar or identical to natural body agonists. Other drugs act on the receptor in a blocking role and are antagonists. An antagonist is a molecule that interferes with or prevents the action of the agonist.
2. A contracting muscle that is opposed by contraction of another associated muscle, the antagonist.

agonist

  1. a substance capable of binding to a molecular target on the cell surface (RECEPTOR) to elicit a biological response. Examples include HORMONES and DRUGS.
  2. a muscle which initiates a response or change in position of a body part acting against an ANTAGONISTIC MUSCLE.

Agonist

A medication that has an affinity for and stimulates the activity of cell receptors that are normally stimulated by naturally occurring substances, including melatonin.

agonist

an agent having a positive action. (1) In pharmacology, a chemical agent that causes a response by a cell when it binds selectively to a specific receptor. Usually refers to a drug which imitates the action of a hormone or neurotransmitter. (2) With reference to skeletal muscles, one, or a group, which is initiating or maintaining a positive action, e.g. the biceps when flexing the elbow. See also antagonist, reciprocal inhibition.

agonist

prime mover, i.e. a muscle that generates sufficient force on contraction to overcome the resistance of its antagonist, so that resultant movement reflects concentric agonist contraction (see antagonist)

agonist

a drug that combines with cellular receptors to initiate drug reactions (see antagonist)

agonist (aˑ·g·nist),

n a muscle that, upon contraction, is balanced by the contraction of a different muscle. Also called
prime mover.

agonist 

1. An agonistic muscle.
2. A substance (e.g. a drug, hormone or neurotransmitter) that binds with a cell receptor to initiate a physiological response similar to that produced by the natural neurotransmitter or hormone. Example: pilocarpine, which mimics the effect of acetylcholine acting on cholinergic receptors. See antagonist.

ag·o·nist

(ag'ŏn-ist)
1. Denoting a muscle in a state of contraction, with reference to its opposing muscle, or antagonist.
2. A drug capable of combining with receptors to initiate drug actions; it possesses affinity and intrinsic activity.
[G. agōn, a contest]

agonist (ag´ənist),

n 1. an organ, gland, muscle, or nerve center that is so connected physiologically with another that the two function simultaneously in forwarding a given process, such as when two muscles pull on the same skeletal member and receive a nervous excitation at the same time. Opposite: antagonist.
2. a drug or other substance having a specific cellular affinity that produces a predictable response.

agonist

1. in physiology a muscle which in contracting to move a part is opposed by another muscle (the antagonist).
2. in pharmacology, a drug which has affinity for the cellular receptors of another drug or natural substance and which produces a physiological effect.

adrenergic agonist (2)
see adrenergic agents.
cholinergic agonist (2)
partial agonist (2)
a drug that combines with the relevant receptors but not with the efficiency of the agonist.
References in periodicals archive ?
To allow the crystallization of ER[alpha] bound to the environmental molecules acting essentially as partial agonists that are unable to induce a stable conformation of the LBD, we used the ER[alpha]-Y537S LBD mutant described previously by Nettles et al.
Relevance of Vilazodone's 5-HT1A receptor partial agonist effect
Table Neurotransmitter Systems in the Brain Involved in Different Stages of the Addiction Cycle and Existing and Potential Pharmacotherapies Targeting Them in the Treatment of Alcohol Dependence Neurotransmitter System Existing and Potential Pharmacotherapies Dopamine system Dopamine receptor partial agonists * [D.
GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists.
Vilazodone, if approved, will be a welcome addition to the treatment armamentarium for patients who suffer from depression, due to its overall efficacy and safety profile, combined with a novel mechanism of action as both an inhibitor of serotonin reuptake and a serotonin 1A receptor partial agonist.
GLYX-13 is a selective NMDA receptor partial agonist, a new class of central nervous system-active compounds discovered by Naurex scientists.
OBJECTIVES: We assessed the ability of generalized concentration addition (GCA) to predict effects of combinations of full AhR agonists with partial agonists or competitive antagonists.
GLYX-13 is Naurex's lead glycine-site functional partial agonist (GFPA) selective modulator of the NMDA receptor.
Given the role that the AhR plays in critical physiologic functions and the potential limitations in assessing the significance of exposures to contaminant mixtures, we propose that a broader perspective and a complementary biological approach be considered, specifically because the cumulative biological effects of agonists, partial agonists, and antagonists are impossible to predict from analytical assays.
is a private company developing novel therapies for depression and other CNS disorders based on a new mechanism of action for modulating the NMDA receptor in a safe way-glycine-site functional partial agonists (GFPAs).
BIND technology for cell-based assays offers an orthogonal screening tool to access new hits and lead molecules that are not detected by other systems, including compounds that undergo G-protein switching, non-G protein coupled pathways, inverse and partial agonists, and receptor desensitization.
Glycine site functional partial agonists, which modulate the NMDA receptor in a novel and selective way, are being developed with the goal of achieving the antidepressant efficacy and rapid onset seen with conventional NMDA receptor modulators, but without the psychotomimetic side effects that have limited the utility of these agents in the past.